Anti-mannose binding lectin antibodies in sera of Japanese patients with systemic lupus erythematosus

R. Takahashi, A. Tsutsumi, K. Ohtani, D. Goto, I. Matsumoto, S. Ito, N. Wakamiya, T. Sumida

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Mannose-binding lectin (MBL) is a key element in innate immunity with functions and structure similar to that of complement C1q. It has been reported that MBL deficiency is associated with occurrence of systemic lupus erythematosus (SLE). We hypothesized that anti-MBL antibodies, if present, would affect the occurrence or disease course of SLE, by reduction of serum MBL levels, interference of MBL functions, or binding to MBL deposited on various tissues. To address this hypothesis, we measured the concentration of anti-MBL antibodies in sera of 111 Japanese SLE patients and 113 healthy volunteers by enzyme immunoassay. The titres of anti-MBL antibodies in SLE patients were significantly higher than those in healthy controls. When the mean + 2 standard deviations of controls was set as the cut off point, individuals with titres of anti-MBL antibodies above this level were significantly more frequent in SLE patients (9 patients) than in controls (2 persons). One SLE patient had an extremely high titre of this antibody. No associations of titres of anti-MBL antibodies and (i) genotypes of MBL gene, (ii) concentrations of serum MBL, or (iii) disease characteristics of SLE, were apparent. Thus, we have confirmed that anti-MBL antibodies are indeed present in sera of some patients with SLE, but the significance of these autoantibodies in the pathogenesis of SLE remains unclear.

Original languageEnglish
Pages (from-to)585-590
Number of pages6
JournalClinical and Experimental Immunology
Volume136
Issue number3
DOIs
Publication statusPublished - Jun 1 2004

Fingerprint

Mannose-Binding Lectin
Systemic Lupus Erythematosus
Antibodies
Serum
Complement C1q
Immunoenzyme Techniques
Innate Immunity
Autoantibodies
Healthy Volunteers

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Anti-mannose binding lectin antibodies in sera of Japanese patients with systemic lupus erythematosus. / Takahashi, R.; Tsutsumi, A.; Ohtani, K.; Goto, D.; Matsumoto, I.; Ito, S.; Wakamiya, N.; Sumida, T.

In: Clinical and Experimental Immunology, Vol. 136, No. 3, 01.06.2004, p. 585-590.

Research output: Contribution to journalArticle

Takahashi, R, Tsutsumi, A, Ohtani, K, Goto, D, Matsumoto, I, Ito, S, Wakamiya, N & Sumida, T 2004, 'Anti-mannose binding lectin antibodies in sera of Japanese patients with systemic lupus erythematosus', Clinical and Experimental Immunology, vol. 136, no. 3, pp. 585-590. https://doi.org/10.1111/j.1365-2249.2004.02477.x
Takahashi, R. ; Tsutsumi, A. ; Ohtani, K. ; Goto, D. ; Matsumoto, I. ; Ito, S. ; Wakamiya, N. ; Sumida, T. / Anti-mannose binding lectin antibodies in sera of Japanese patients with systemic lupus erythematosus. In: Clinical and Experimental Immunology. 2004 ; Vol. 136, No. 3. pp. 585-590.
@article{627eb520b61543fe8b5f399217bd4a06,
title = "Anti-mannose binding lectin antibodies in sera of Japanese patients with systemic lupus erythematosus",
abstract = "Mannose-binding lectin (MBL) is a key element in innate immunity with functions and structure similar to that of complement C1q. It has been reported that MBL deficiency is associated with occurrence of systemic lupus erythematosus (SLE). We hypothesized that anti-MBL antibodies, if present, would affect the occurrence or disease course of SLE, by reduction of serum MBL levels, interference of MBL functions, or binding to MBL deposited on various tissues. To address this hypothesis, we measured the concentration of anti-MBL antibodies in sera of 111 Japanese SLE patients and 113 healthy volunteers by enzyme immunoassay. The titres of anti-MBL antibodies in SLE patients were significantly higher than those in healthy controls. When the mean + 2 standard deviations of controls was set as the cut off point, individuals with titres of anti-MBL antibodies above this level were significantly more frequent in SLE patients (9 patients) than in controls (2 persons). One SLE patient had an extremely high titre of this antibody. No associations of titres of anti-MBL antibodies and (i) genotypes of MBL gene, (ii) concentrations of serum MBL, or (iii) disease characteristics of SLE, were apparent. Thus, we have confirmed that anti-MBL antibodies are indeed present in sera of some patients with SLE, but the significance of these autoantibodies in the pathogenesis of SLE remains unclear.",
author = "R. Takahashi and A. Tsutsumi and K. Ohtani and D. Goto and I. Matsumoto and S. Ito and N. Wakamiya and T. Sumida",
year = "2004",
month = "6",
day = "1",
doi = "10.1111/j.1365-2249.2004.02477.x",
language = "English",
volume = "136",
pages = "585--590",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Anti-mannose binding lectin antibodies in sera of Japanese patients with systemic lupus erythematosus

AU - Takahashi, R.

AU - Tsutsumi, A.

AU - Ohtani, K.

AU - Goto, D.

AU - Matsumoto, I.

AU - Ito, S.

AU - Wakamiya, N.

AU - Sumida, T.

PY - 2004/6/1

Y1 - 2004/6/1

N2 - Mannose-binding lectin (MBL) is a key element in innate immunity with functions and structure similar to that of complement C1q. It has been reported that MBL deficiency is associated with occurrence of systemic lupus erythematosus (SLE). We hypothesized that anti-MBL antibodies, if present, would affect the occurrence or disease course of SLE, by reduction of serum MBL levels, interference of MBL functions, or binding to MBL deposited on various tissues. To address this hypothesis, we measured the concentration of anti-MBL antibodies in sera of 111 Japanese SLE patients and 113 healthy volunteers by enzyme immunoassay. The titres of anti-MBL antibodies in SLE patients were significantly higher than those in healthy controls. When the mean + 2 standard deviations of controls was set as the cut off point, individuals with titres of anti-MBL antibodies above this level were significantly more frequent in SLE patients (9 patients) than in controls (2 persons). One SLE patient had an extremely high titre of this antibody. No associations of titres of anti-MBL antibodies and (i) genotypes of MBL gene, (ii) concentrations of serum MBL, or (iii) disease characteristics of SLE, were apparent. Thus, we have confirmed that anti-MBL antibodies are indeed present in sera of some patients with SLE, but the significance of these autoantibodies in the pathogenesis of SLE remains unclear.

AB - Mannose-binding lectin (MBL) is a key element in innate immunity with functions and structure similar to that of complement C1q. It has been reported that MBL deficiency is associated with occurrence of systemic lupus erythematosus (SLE). We hypothesized that anti-MBL antibodies, if present, would affect the occurrence or disease course of SLE, by reduction of serum MBL levels, interference of MBL functions, or binding to MBL deposited on various tissues. To address this hypothesis, we measured the concentration of anti-MBL antibodies in sera of 111 Japanese SLE patients and 113 healthy volunteers by enzyme immunoassay. The titres of anti-MBL antibodies in SLE patients were significantly higher than those in healthy controls. When the mean + 2 standard deviations of controls was set as the cut off point, individuals with titres of anti-MBL antibodies above this level were significantly more frequent in SLE patients (9 patients) than in controls (2 persons). One SLE patient had an extremely high titre of this antibody. No associations of titres of anti-MBL antibodies and (i) genotypes of MBL gene, (ii) concentrations of serum MBL, or (iii) disease characteristics of SLE, were apparent. Thus, we have confirmed that anti-MBL antibodies are indeed present in sera of some patients with SLE, but the significance of these autoantibodies in the pathogenesis of SLE remains unclear.

UR - http://www.scopus.com/inward/record.url?scp=2542564198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542564198&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2249.2004.02477.x

DO - 10.1111/j.1365-2249.2004.02477.x

M3 - Article

C2 - 15147364

AN - SCOPUS:2542564198

VL - 136

SP - 585

EP - 590

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 3

ER -